Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The Company has two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical stage of development. The Company’s lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia (AML). The Company is developing a platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). The Company’s inflammatory disease programs include CRACM Ion Channel Inhibitors and IL-12/23 Inhibitors.